RobertoACalleMDFACE, FACP

Diabetes, Lipid Metabolism, Obesity

Executive Medical Director

Dr. Calle is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Regeneron Pharmaceuticals
777 Old Sawmill River Road
Tarrytown, NY 10591

Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1987 - 1989
University of MichiganResidency, Internal Medicine, 1984 - 1987
University of Puerto Rico School of MedicineClass of 1984, MD

PubMed

19 citations
The prevalence of low muscle mass associated with obesity in the USA.
Dana J Murdock, Ning Wu, Joseph S Grimsby, Roberto A Calle, Stephen Donahue
Skeletal Muscle. 2022-12-21
34 citations
Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.
Arun J Sanyal, Sudha S Shankar, Roberto A Calle, Anthony E Samir, Claude B Sirlin
Nature Medicine. 2022-03-01
107 citations
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a...
Roberto A. Calle, Neeta B. Amin, Santos Carvajal-Gonzalez, Trenton T. Ross, Arthur Bergman
Nature Medicine. 2021-10-01

Journal Articles

A First-In-Patient (Phase Ib) Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia
J. Crawford, R.A. Calle, S.M. Collins, Y. Weng, Shannon L. Lubaczewski, C. Buckridge, E. Q Wang, M.A. Harrington, A. Tarachandani, M.I. Rossulek, J.H Revkin., Clinical Cancer Research, 2023
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
A. J. Sanyal, S.S. Shankar, K.P. Yates, J. Bolognese, E. Daly, C. A. Dehn, B. Neuschwander-Tetri, K. Kowdley, R. Vuppalanchi, C. Behling, J. Tonascia, A. Samir, C. Sir..., Nature Medicine, 2023
Repeatability of MRI biomarkers in non-alcoholic fatty liver disease: the NIMBLE Consortium
K. Fowler, S. Venkatesh, N. Obuchowski, M. Middleton, J. Chen, K. Pepin, J. Magnuson, K. Brown, D. Batakis, W. Henderson, S. Shankar, T. Kamphaus, A. Pasek, R. Calle, ..., Radiology, 2023
The Prevalence of Low Muscle Mass Associated with Obesity in the USA
D.J. Murdock, N. Wu, J.S. Grimsby, R.A. Calle, S. Donahue, D.J. Glass, M.W. Sleeman, R.J. Sanchez, Skeletal Muscle, 2022
Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial
David J. Kazierad, Kristin Chidsey, Veena R. Somayaji, Arthur J. Bergman, Morris J. Birnbaum, Roberto A. Calle, Med, 7/9/2021
Join now to see all

Co-Chair, Non-Invasive Biomarkers of Metabolic Liver Disease - NIMBLE FNIH Project 2018 - Present
Member, American Diabetes Association New England - Community Leaders Board 2017 - Present
Co-Chair, FNIH Biomarkers Consortium - Metabolic Disorders Steering Committee 2014 - Present
Member, FNIH Biomarkers Consortium - Metabolic Disorders Steering Committee 2009 - 2013